Evidence map›Paper›PMID 38665866›Full record

ArticleBiochemia medica2024

Common P-glycoprotein (

Ana Marija Slišković, Jozefina Palić, Tamara Božina, Lana Ganoci, Majda Vrkić Kirhmajer, Vladimir Trkulja, Joško Bulum, Livija Šimičević

Open access · diamondAbstract read
In one paragraph

Article in Biochemia medica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ana Marija SliškovićDepartment of Cardiovascular Diseases, University Hospital Centre Zagreb, Zagreb, Croatia.
Jozefina PalićDepartment of Medical Chemistry, Biochemistry and Clinical Chemistry, University of Zagreb School of Medicine, Zagreb, Croatia.
Tamara BožinaDepartment of Medical Chemistry, Biochemistry and Clinical Chemistry, University of Zagreb School of Medicine, Zagreb, Croatia.
Lana GanociDivision of Pharmacogenomics and Therapy Individualization, Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia.
Majda Vrkić KirhmajerDepartment of Cardiovascular Diseases, University Hospital Centre Zagreb, Zagreb, Croatia.
Vladimir TrkuljaDepartment of Pharmacology, University of Zagreb School of Medicine, Zagreb, Croatia.
Joško BulumDepartment of Cardiovascular Diseases, University Hospital Centre Zagreb, Zagreb, Croatia.
Livija ŠimičevićDepartment of Medical Chemistry, Biochemistry and Clinical Chemistry, University of Zagreb School of Medicine, Zagreb, Croatia.
University Hospital Centre Zagreb · HRUniversity of Zagreb · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Considering conflicting previous reports, we aimed to evaluate whether the common Materials and methods: We report preliminary data from a larger nested case-control study. Consecutive adults started on rivaroxaban for any indication requiring > 6 months of treatment were followed-up to one year. Patients who experienced major or non-major clinically relevant bleeding during the initial 6 months were considered cases, whereas subjects free of bleeding over > 6 months were controls. The polymorphisms of interest (rs1128503, rs2032582, rs1045642, rs4148738) were in a strong linkage disequilibrium, hence patients were classified regarding the "load" of variant alleles: 0-2, 3-5 or 6-8. The three subsets were balanced regarding a range of demographic, comorbidity, comedication and genetic characteristics. A logistic model was fitted to probability of bleeding. Results: There were 60 cases and 220 controls. Raw proportions of cases were similar across the subsets with increasing number of Conclusions: The evaluated common

Indexed as

ATP Binding Cassette Transporter, Subfamily BHemorrhagePolymorphism, Single NucleotideRivaroxabanAgedCase-Control StudiesFactor Xa InhibitorsFemaleHumansMaleMiddle AgedRisk FactorsABCB1 protein, humanATP Binding Cassette Transporter, Subfamily BFactor Xa InhibitorsRivaroxabanadverse drug reactionscardiovascular diseasehemorrhagepharmacogeneticsrisk factorsrivaroxaban

Identifiers

PMID38665866
PMCPMC11042566
OpenAlexW4394855002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.